Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ankur Rughani

Pediatric Endocrinology Oklahoma City, OK Medical Doctor

NPI 1346628856 CMS profile 1351764

3330 Nw 56Th St Ste 500, Oklahoma City, OK 73112

Open in the dashboard

General payments

$20,380

228 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ankur Rughani of Oklahoma City, OK is reported in the CMS Open Payments database as having received $20,380 across 228 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,260 92
2024 General $3,604 68
2023 General $1,780 40
2022 General $612 27
2019 General $125 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ankur Rughani
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Ankur Rughani were reported at $14,260. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Ankur Rughani Pediatric Endocrinology median Middle half National median
2019 $125 $196 $68–$845 $163
2020 $0 $124 $37–$722 $114
2021 $0 $134 $35–$691 $132
2022 $612 $177 $47–$726 $149
2023 $1,780 $236 $75–$887 $160
2024 $3,604 $259 $91–$979 $164
2025 $14,260 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sanofi-Aventis U.S. LLC $12,330 38 payments
  2. Alexion Pharmaceuticals, Inc. $2,288 8 payments
  3. Kyowa Kirin, Inc. $1,369 7 payments
  4. Ascendis Pharma, Inc. $588 20 payments
  5. Tandem Diabetes Care, Inc. $517 17 payments
  6. Tolmar, Inc. $421 14 payments
  7. AbbVie, Inc. $341 16 payments
  8. Beta Bionics, Inc. $320 8 payments
  9. Xeris Pharmaceuticals, Inc. $229 12 payments
  10. Abbott Laboratories $217 12 payments
  11. Other $1,761 76 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,416 7 payments
  2. Food and Beverage $5,896 216 payments
  3. Consulting Fee $1,980 2 payments
  4. Education $88 3 payments
Products named General payments · program years 2019–2025
  1. TZIELD $10,410 37 payments
  2. CRYSVITA $1,322 5 payments
  3. STRENSIQ $1,023 5 payments
  4. SKYTROFA $546 18 payments
  5. t:slim X2 Insulin Pump with Control-IQ $517 17 payments
  6. LUPRON DEPOT $341 16 payments
  7. FENSOLVI $336 10 payments
  8. iLet Insulin Infusion Kit Inset $277 6 payments
  9. iLet Insulin Infusion Kit Contact Detach $277 6 payments
  10. iLet Bionic Pancreas $277 6 payments
  11. Other $3,238 126 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

228 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record